Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape

Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas

(2016) Nathalie L. Albert et al.   NEURO-ONCOLOGY

Diffusion and Perfusion MRI to Differentiate Treatment-Related Changes Including Pseudoprogression from Recurrent Tumors in High-Grade Gliomas with Histopathologic Evidence

(2015) A.J. Prager et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Immunotherapy response assessment in neuro-oncology: a report of the RANO working group

(2015) Hideho Okada et al.   LANCET ONCOLOGY

Pitfalls in the Neuroimaging of Glioblastoma in the Era of Antiangiogenic and Immuno/Targeted Therapy – Detecting Illusive Disease, Defining Response

(2015) Raymond Y. Huang et al.   Frontiers in Neurology

Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-l-tyrosine PET

(2014) Norbert Galldiks et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

The Diagnosis and Treatment of Pseudoprogression, Radiation Necrosis and Brain Tumor Recurrence

(2014) Kashif Parvez et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Emerging applications for ferumoxytol as a contrast agent in MRI

(2014) Mustafa R. Bashir et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

Pseudoprogression in patients with glioblastoma: clinical relevance despite low incidence

(2014) A. Radbruch et al.   NEURO-ONCOLOGY

Defining pseudoprogression in glioblastoma multiforme

(2013) E. Van Mieghem et al.   EUROPEAN JOURNAL OF NEUROLOGY

Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients

(2013) K. Herrmann et al.   NEURO-ONCOLOGY

MRI perfusion in determining pseudoprogression in patients with glioblastoma

(2012) Robert J. Young et al.   CLINICAL IMAGING

Late and Prolonged Pseudoprogression in Glioblastoma After Treatment With Lomustine and Temozolomide

(2012) Moritz Stuplich et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of 11C-methionine PET parametric response map for monitoring WT1 immunotherapy response in recurrent malignant glioma

(2012) Yasuyoshi Chiba et al.   JOURNAL OF NEUROSURGERY

Treatment-Related Change Versus Tumor Recurrence in High-Grade Gliomas: A Diagnostic Conundrum—Use of Dynamic Susceptibility Contrast-Enhanced (DSC) Perfusion MRI

(2011) Girish M. Fatterpekar et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

The Concepts, Diagnosis and Management of Early Imaging Changes after Therapy for Glioblastomas

(2011) P. Sanghera et al.   CLINICAL ONCOLOGY

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

(2010) John H. Sampson et al.   JOURNAL OF CLINICAL ONCOLOGY

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Induction of CD8+ T-Cell Responses Against Novel Glioma–Associated Antigen Peptides and Clinical Activity by Vaccinations With α-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma

(2010) Hideho Okada et al.   JOURNAL OF CLINICAL ONCOLOGY

Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity

(2010) Benjamin M. Ellingson et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

MR perfusion and diffusion imaging in the follow-up of recurrent glioblastoma treated with dendritic cell immunotherapy: a pilot study

(2010) Matej Vrabec et al.   NEURORADIOLOGY

Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression

(2009) Elizabeth R. Gerstner et al.   JOURNAL OF NEURO-ONCOLOGY

Radiological progression of cerebral metastases after radiosurgery: assessment of perfusion MRI for differentiating between necrosis and recurrence

(2009) Friso W. A. Hoefnagels et al.   JOURNAL OF NEUROLOGY

Differentiation of Recurrent Glioblastoma Multiforme from Radiation Necrosis after External Beam Radiation Therapy with Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging

(2009) Ramon F. Barajas et al.   RADIOLOGY

Relative Cerebral Blood Volume Values to Differentiate High-Grade Glioma Recurrence from Posttreatment Radiation Effect: Direct Correlation between Image-Guided Tissue Histopathology and Localized Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging Measurements

(2008) L.S. Hu et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Distinguishing Recurrent Intra-Axial Metastatic Tumor from Radiation Necrosis Following Gamma Knife Radiosurgery Using Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging

(2008) R.F. Barajas et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Incidence of early pseudo‐progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide

(2008) Walter Taal et al.   CANCER

MGMTPromoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients

(2008) Alba A. Brandes et al.   JOURNAL OF CLINICAL ONCOLOGY

PET Imaging of Cancer Immunotherapy

(2008) P. C. Tumeh et al.   JOURNAL OF NUCLEAR MEDICINE

Diagnostic Accuracy of 11C-Methionine PET for Differentiation of Recurrent Brain Tumors from Radiation Necrosis After Radiotherapy

(2008) Y. Terakawa et al.   JOURNAL OF NUCLEAR MEDICINE

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas

(2008) Dieta Brandsma et al.   LANCET ONCOLOGY

Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: Pitfalls in neurooncology

(2008) Alba A. Brandes et al.   NEURO-ONCOLOGY